The research group of Dr. Beà has a longstanding history in tumor genetics, particularly in B cell neoplasias. Her research team belongs to the Area 5 (Oncology-Haematology) of IDIBAPS. The group has been recognized as a pre-Consolidated Group by the “Agència de Gestió d’Ajuts Universitaris i de Recerca” in 2018. The main research lines of the group are: i) Identification of somatic mutations, structural variants and genomic alterations in B cell neoplasias; ii) Identification of more accurate diagnostic, prognostic, and predictive biomarkers; and iii) Functional validation of recurrently mutated genes. All the projects have a clear translational basic-clinic perspective. In the last years she has performed a comprehensive molecular characterization of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and leukemic chronic B-cell lymphoproliferative disorders (B-CLPD). The major achievements (last 5 years), reflected by publications of Dr Beà as senior author are:
i)    Characterization of cyclin D1-negative MCL as a clinical and genetic variant similar to conventional MCL, and proposal of molecular tools for proper identification (Blood 2018, Blood 2013)
ii)   Identification of the profile of mutations/genomic alterations in MCL using whole-genome and exome sequencing, that lead to the identification of molecular mechanism that open new perspectives for the management of the patients offering potential targets for therapeutic intervention (PNAS 2013). She has also two reviews of the genetic alterations in MCL (J Intern Med 2017; Curr Oncol Rep 2017).
iii)  Development of a custom array for the identification of high-risk CLL patients that will be commercialized by the company qGenomics (Haematologica 2014), and characterization of increased genomic complexity and IGHV mutational status as key predictors of outcome of CLL patients with TP53 disruption (Genes, Chr Can 2015).        
iv) Comprehensive characterization of the structural alterations of 506 CLL cases in the context of the International Cancer Genome Consortium-Chronic lymphocytic leukemia (ICGC-CLL) Genome project (Nature 2015, second author). Dr Beà performed and coordinated the copy number and structural variant analysis.
v)  Identification of expression profiles as robust molecular classifiers for leukemic B-cell CLPD that allows the refinement of the diagnosis (Haematologica 2017). Characterization of splenic diffuse red pulp small B-cell lymphoma  (Am J Surg Pathol. 2016).
As principal investigator she has had continuous and overlapping funding: 4 consecutive Fondo de Investigación Sanitaria projects from Instituto de Salud Carlos III, Fundació La Marató TV3, Asociacion Española contra el Cancer  and Association for International Cancer Research. She participates in 4 other projects and participated in 10 finished projects. She is member of the ICGC-CLL, European Mantle Cell Lymphoma Network, Lymphoma Research Foundation, and Lymphoma /Leukemia Molecular Profiling Project Consortium, Centro de Investigación Biomédia en Red de Cáncer, and has a large network of national/international collaborations. She has been invited to give 29 conferences (16 international), has directed four doctoral theses and participates in the formation of students/professionals. She organized the IDIBAPS international workshop “Translational Genomics in Biomedicine” (March 2014), and is member of the “Comissió Assessora de la plataforma de Genòmica Funcional” from IDIBAPS.